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ABSTRACT
Zebrafish is considered a model organism, not only for the
study of the biological functions of vertebrates but also as a tool
to analyze the effects of some drugs or toxic agents. Five opioid
precursor genes homologous to the mammalian opioid propep-
tide genes have recently been identified; one of these, the
zebrafish proenkephalin, codes a novel heptapeptide, the Met-
enkephalin-Gly-Tyr (MEGY). To analyze the pharmacological
properties of this novel ligand, we have labeled it with tritium
([3H]MEGY). In addition, we have also synthesized two analogs:
(D-Ala2)-MEGY (Y-D-Ala-GFMGY) and (D-Ala2, Val5)-MEGY (Y-
D-Ala-GFVGY). The binding profile of these three agents has
been studied in zebrafish and rat brain membranes. [3H]MEGY
presents one binding site in zebrafish, as well as in rat brain
membranes, although it shows a slight higher affinity in ze-
brafish brain. The observed saturable binding is displaced by
naloxone, thus confirming the opioid nature of the binding sites.
Competition binding assays indicate that the methionine resi-
due is essential for high-affinity binding of MEGY and probably
of other peptidic agonists in zebrafish, whereas the change of
a Gly for a D-Ala does not dramatically affect the ligand affinity.
Our results show that the percentage of [3H]MEGY displaced
by all the ligands studied is higher than 100%, thus inferring
that naloxone (used to determine nonspecific binding) does not
bind to all the sites labeled by [3H]MEGY. Therefore, we can
deduct that some of the MEGY binding sites should not be
considered classical opioid sites.
The endogenous opioid peptides such as enkephalins, -en-
dorphins, and dynorphins exert their actions mainly by act-
ing on the opioid receptors present in the nervous system.
These peptides are generated by the processing of larger
precursors that are encoded in the genome: proenkephalin
(PENK) (Comb et al., 1982; Gubler et al., 1982; Noda et al.,
1982), proopiomelanocortin (POMC) (Takahashi et al., 1981),
and prodynorphin (Horikawa et al., 1983). These precursors
and the corresponding encoded peptides have been mainly
identified in vertebrates, and the evolution of this gene fam-
ily has been widely analyzed (Dores et al., 2002). However,
little is known about the pharmacological activity of newly
discovered endogenous peptides from lower vertebrates.
The zebrafish has been considered a model organism in
molecular biology and development (Golling et al., 2002), but
nowadays it is also being used to analyze the genetic basis of
human diseases, and it has been proposed as a candidate
organism for the study of interactions between the genome
and the environment (Ingham, 1997; Dooley and Zon, 2000;
Fishman, 2001). Since drug addiction presents not only a
genetic component but also is affected by outer influences,
the zebrafish can be considered a valid model to unravel the
molecular basis of drug tolerance and dependence (Darland
and Dowling, 2001; Dlugos and Rabin, 2003; Pichler et al.,
2003). For this reason, we are studying the zebrafish opioid
system, and up to now we have characterized five opioid
precursors from the zebrafish: zfPENK, zfPENK-like (a du-
plicate PENK gene) (Gonza´lez-Nun˜ez et al., 2003a), zfPOMC,
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zfPOMC-like (Gonza´lez-Nun˜ez et al., 2003c), and zfPNOC
(Gonza´lez-Nun˜ez et al., 2003b). These precursors contain
novel opioid peptides that can display different pharmacolog-
ical properties than their counterparts in mammals. In par-
ticular, mammals present an enlarged form of Met-enke-
phalin [Met-enkephalin-Arg-Phe (MERF)] that is different
from its homolog in zebrafish, the Met-enkephalin-Gly-Tyr
(MEGY). It is important to note that the change of Arg by Gly
implies not only the substitution of a bulky amino acid by a
small residue but also a net loss of a positive charge in the
peptide that can be significant for its binding properties.
The mammalian MERF was first isolated from bovine ad-
renal medulla (Stern et al., 1979), and it has been shown that
this peptide displays important biological functions (Sharma
et al., 1993) as, for example, antinociception (Inturrisi et al.,
1980) and antitusive properties (Kamei et al., 1994). The
binding properties of MERF and some of its analogs (Bozo et
al., 2000; Toth et al., 2003) have been widely studied in
amphibian (Wollemann et al., 1994) and mammalian brain
(Benyhe et al., 1997, 1999; Kim et al., 2000), and it has
been shown that MERF binds to opioid receptors with high
affinity.
Taking the above into consideration, we aimed to charac-
terize the binding profile of MEGY peptide in zebrafish, the
organism in which this peptide is naturally present as an
endogenous opioid ligand, and in rat brain membranes, as a
representative model of the mammalian opioid system. In
this way, we can compare the affinities of this peptide in
these two species.
To achieve this objective, we have synthesized and labeled
the MEGY peptide ([3H]MEGY; 20 Ci/mmol) and performed
binding assays. Two MEGY analogs were also synthesized:
(D-Ala2)-MEGY (Y-D-Ala-GFMGY) and (D-Ala2, Val5)-MEGY
(Y-D-Ala-GFVGY). The change of a Gly by a D-Ala confers
resistance against proteases such as dipeptidyl-aminopepti-
dases, which remove the N-terminal dipeptide Tyr1-Gly2
(Hazato et al., 1982; van Amsterdam et al., 1983). In addi-
tion, the substitution of Met by Val may help to determine
the importance of the methionine residue for the specific
opioid binding.
Materials and Methods
Drugs and Radioligands. Morphine was obtained from the
Spanish Ministry of Health (Madrid, Spain), and naloxone and Met-
enkephalin were obtained from Sigma-Aldrich (St. Louis, MO).
[3H]Diprenorphine (50 Ci/mmol) was purchased from PerkinElmer
Life and Analytical Sciences (Boston, MA). G. Arsequell and G.
Valencia (Consejo Superior de Investigaciones Cientı´ficas, Barce-
lona, Spain) originally synthesized MEGY. [3H]MEGY (20 Ci/mmol),
unlabeled MEGY, and its two analogs (D-Ala2)-MEGY (Tyr-D-Ala-
Gly-Phe-Met-Gly-Tyr) and (D-Ala2, Val5)-MEGY (Tyr-D-Ala-Gly-Phe-
Val-Gly-Tyr) were synthesized by G. Toth at the Institute of Bio-
chemistry, Biological Research Centre, Hungarian Academy of
Sciences. All other reagents used were of analytical grade.
Peptide Synthesis. The endogenous MEGY, its two analogs,
(D-Ala2)-MEGY and (D-Ala2, Val5)-MEGY, and the precursor peptide
for tritiation (35I-Tyr-Gly-Gly-Phe-Met-Gly-Tyr) were synthesized
by the solid-phase peptide synthesis method using the published Boc
chemistry procedure (To´th et al., 1997a). The crude peptides were
purified by reverse-phase high-performance liquid chromatography
(HPLC) using a Vydac 218TP1010 column (W. R. Grace & Co.,
Columbia, MD). The peptide was eluted by the acetonitrile/0.1%
trifluoroacetic acid solvent system using a linear gradient. The struc-
ture of the peptides was confirmed by mass spectrometry.
[35-3H]MEGY was prepared by catalytic dehalogenation of the
precursor peptide using 3H2 gas and PdO/BaSO4 (Merck, Darmstadt,
Germany) as the catalyst in the presence of triethylamine (To´th et
al., 1997b). The crude tritiated peptide was purified by HPLC as
previously described. The purity of the final product was established
by analytical HPLC using a Vydac 218TP46 column (W. R. Grace &
Co.), and the degree of purity observed was 95%. The radioactivity
was measured using a Packard liquid scintillation counter (Canberra
Industries, Meriden, CT). The specific radioactivity was 20 Ci/mmol.
The purified peptide was stored in ethanol under liquid nitrogen at
a concentration of 1 mCi/ml.
Animals. Adult zebrafish Danio rerio were obtained from a local
pet supplier, maintained at 25 to 28°C, and fed once a day. In all the
experiments, fish from both sexes were used. Adult Sprague-Dawley
rats ranging from 200 to 280 g were kept in cages with a 12-h
light/dark cycle and free access to food and water. Animals were
handled according to the guidelines of the European Communities
Council directive of November 24, 1986 (86/609/EEC) and in all cases
were treated in accordance with the Declaration of Helsinki and/or
with The Guide for the Care and Use of Laboratory Animals as
adopted and promulgated by the U.S. National Institutes of Health
and the Spanish Ethical Committee.
Membrane Preparation. Brains from zebrafish and rats were
extracted and kept on dry ice and homogenized with a Kinematica
Polytron (Basel, Switzerland) in 50 mM Tris-HCl, pH 7.4 (assay
buffer), with protease inhibitors (0.1 mg/ml bacitracin, 3.3 M cap-
topril, and 0.33 M thiorphan). The homogenates were centrifuged
at 6000g for 15 min at 4°C, and the pellet was washed once in assay
buffer, homogenized, and centrifuged. Membranes were resuspended
in ice-cold assay buffer with protease inhibitors, and protein concen-
tration was determined by the Lowry method (Onishi and Barr
Modification; Sigma-Aldrich).
Saturation Binding Assays. Either 30 (zebrafish) or 100 g
(rat) of protein was incubated with different concentrations of the
radioligand [3H]MEGY for 1.5 h at 25°C in a final volume of 500 l.
Naloxone (10 M) was used to determine nonspecific binding. After
incubation, the reaction was stopped by adding 4 ml of ice-cold assay
buffer; the mixture was rapidly filtrated using a Brandel cell har-
vester (Brandel Inc., Gaithersburg, MD) and washed two times onto
GF/B glass-fiber filters that were presoaked with 0.2% polyethyleni-
mine for at least 1 h. The filters were placed in scintillation vials and
incubated overnight at room temperature in EcoScint A scintillation
liquid (National Diagnostics, Atlanta, GA). Radioactivity was
counted using a Beckman Coulter, Inc. (Fullerton, CA) scintillation
counter. All experiments were performed in duplicate and repeated
at least three times.
Competition Binding Assays. Reactions were performed as de-
scribed under “Saturation Binding Assays”, except that the radioli-
gand [3H]diprenorphine was used at 0.96 nM in the case of the
zebrafish and 0.45 nM in the case of the rat brain homogenates, and
[3H]MEGY was used at 1.65 nM in the case of the zebrafish and 3.85
nM in the case of the rat brain homogenates. The labeled ligands
were displaced by several unlabeled compounds at a concentration
range of 0.3 nM to 10 M. All experiments were performed in
duplicate and repeated several times.
Data Analysis. Specific binding was defined as the difference
between total binding and nonspecific binding (measured in the
presence of 10 M naloxone). Data were analyzed using Prism soft-
ware (GraphPad Software Inc., San Diego, CA), and affinity constant
(KD), receptor density (Bmax), and inhibition constant (Ki) values for
each ligand were obtained. Ki values were calculated using Graph-
Pad software using the Cheng and Prusoff correction, which corrects
for the concentration of radioligand used in each experiment and the
affinity of the radioligand for its binding site (KD). In all cases, data
were fit to the one- or two-site binding model. In saturation binding
assays, data were fit to either nonlinear function or the linear trans-
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formation (Scatchard plot, bound/free versus bound), whereas in
competition binding assays, data were fit to the one- and two-site
competition models and compared using the nonlinear least-squares
curve-fitting, which is based upon a statistical F test.
Results
Saturation Binding Assays of [3H]MEGY in Zebrafish
and Rat Brain Membranes. The ability of [3H]MEGY to
bind opioid receptors from zebrafish, an organism in which
this peptide is naturally present (Gonza´lez-Nun˜ez et al.,
2003a), and from mammals, in which MERF is the corre-
sponding endogenous peptide, was measured using increas-
ing concentrations of this radioligand in zebrafish and rat
brain membrane homogenates. In both cases, binding was
displaced by naloxone, thus confirming the opioid nature of
these sites. In Fig. 1a, the saturation curve of [3H]MEGY in
zebrafish brain membranes is shown, and the Scatchard
transformation is presented in the inset. The data were bet-
ter fit to the one single-binding site model, with KD  2.39 
0.29 nM and Bmax  255.1  10.84 fmol/mg protein. The
same analysis is presented for rat brain membranes (Fig. 1b),
where data also better fit to the one single-binding site
model, with KD  3.8  0.34 nM and Bmax  308.1  11.45
fmol/mg protein.
Competition Binding Assays Using [3H]Diprenor-
phine. To analyze the ability of MEGY to displace other
conventional opioid compounds, competition binding assays
were performed using [3H]diprenorphine as the radioligand
and MEGY and its two analogs, (D-Ala2)-MEGY and (D-Ala2,
Val5)-MEGY, as unlabeled ligands at a concentration range
of 0.3 nM to 10 M. Figure 2 shows the competition binding
plots of these ligands in zebrafish and rat brain membranes,
Fig. 1. Saturation binding analysis of [3H]MEGY in (a) zebrafish and
(b) rat brain membranes. Insets, Scatchard plots. Results represent
the means  S.E.M. of three independent experiments performed in
duplicate. In both cases, the results fit better to the one single-site
binding model. Either 30 g (zebrafish) or 100 g (rat) of protein was
incubated with different concentrations of [3H]MEGY for 1.5 h at 25°C
in a final volume of 500 l. Nonspecific binding was determined with
10 M naloxone.
Fig. 2. Competition binding assays of [3H]diprenorphine with unlabeled MEGY, (D-Ala2)-MEGY, and (D-Ala2, Val5)-MEGY in zebrafish and rat brain
membranes. Results represent the means  S.E.M. of at least two independent experiments performed in duplicate. Brains were extracted, and
membrane homogenates were obtained as described under Materials and Methods. Thirty (zebrafish) or 100 g (rat) of protein was incubated with
[3H]diprenorphine and increasing concentrations of the MEGY analogs (from 0.3 nM to 10 M) for 1 h at 25°C in a final volume of 500 l. Nonspecific
binding was determined with 10 M naloxone.
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and Table 1 summarizes the Ki values, the percentage of
displacement, and the Hill coefficient shown by each peptide.
It is important to note that in zebrafish brain membranes the
native peptide MEGY fits better to the two-site displacement
model (F 7.414; p 0.0037), whereas all the other displace-
ment curves fit better to the one-site competition model. This
result is also supported by the fact that the Hill coefficient for
MEGY displacement of [3H]diprenorphine in zebrafish brain
is 0.30, whereas for the other ligands this coefficient is
closer to 1 (between 0.65 and 0.90). In zebrafish, the
percentage of binding displaced by the native peptide MEGY
is higher than that observed for the analogs, where (D-Ala2,
Val5)-MEGY shows the lowest ability to displace [3H]di-
prenorphine binding.
Competition Binding Assays Using [3H]MEGY.
[3H]MEGY was also used as the radioligand in competition
binding assays using the unlabeled peptide MEGY and its
two analogs as unlabeled ligands so that it was possible to
determine the influence of the structural changes in the
binding ability. Heterologous displacements with morphine
(nonpeptidic opiate) and Met-enkephalin (an endogenous li-
gand for both species) were also performed. Results are sum-
marized in Fig. 3, where the displacement curves in zebrafish
and in rat brain membranes are shown, and in Table 2, which
summarizes the Ki obtained for each ligand. In all cases, the
one-site displacement model fits better to the experimental
data, although the displacement of [3H]MEGY by morphine
in rat brain can also be adjusted to the two-site displacement
model, with a Hill coefficient of 0.40. The other ligands
studied show a Hill coefficient between 0.86 and 1.61 for
both species. Interestingly, the five ligands tested here prove
to be able to displace more than 100% of the binding in
zebrafish brain membranes (and also to a lower extent in rat
brain), which means that part of the [3H]MEGY binding
cannot be displaced by naloxone. However, these binding
sites are recognized by other peptidic ligands (e.g., MEGY
and Met-enkephalin) and alkaloids such as morphine.
Discussion
Previous work has proved that the zebrafish can be a good
vertebrate model to study the actions of different drugs (Dar-
land and Dowling, 2001; Dlugos and Rabin, 2003; Pichler et
al., 2003). In this work, we show that the zebrafish endoge-
nous opioid peptide MEGY can bind to the opioid receptors
present in zebrafish and rat brain with high affinity and that
this binding is reversed by naloxone. The binding assays of
[3H]MEGY obtained by us give similar saturation curves for
zebrafish and rat brain homogenates, although this peptide
presents a significant higher affinity in zebrafish brain. KD
values obtained for this ligand are in the same range than
what previous studies have found for MERF in mammalian
(6.7  1.9 nM, Benyhe et al., 1997; 10.2  0.5 nM, Kim et al.,
2000) and in amphibian brain (3.6  1.7 nM, Wollemann et
al., 1994). However, the values obtained in mammalian
brains for MERF are higher than the value for MEGY in rat
brain (KD  3.8  0.34 nM); this difference may be because
different methods for preparing the brain membrane homog-
enates have been used. Nevertheless, it should also be con-
sidered that the change of an Arg residue present in MERF
for a Gly residue reduces the molecular volume of the pep-
tide; thus, it can adjust better to the receptor binding pocket.
Given that the use of the nonspecific antagonist [3H]di-
prenorphine as the labeled compound to determine opioid
binding is well documented (Richards and Sadee, 1985; Wood
and Traynor, 1989; Wood et al., 1989; Rodriguez et al., 1992)
and that in our hands [3H]diprenorphine presents two differ-
ent binding sites in zebrafish brain (KD values 0.08 and 17
nM) (V. Gonza´lez-Nun˜ez, R. E. Rodriguez, A. Barrallo, and J.
Traynor, unpublished results), we have used it in competi-
tion binding assays to analyze the relative efficiency of
Fig. 3. Competition binding assays of [3H]MEGY and several unlabeled
ligands in (a) zebrafish and (b) rat brain membranes. Results are from a
representative experiment performed in duplicate and repeated twice.
Note that in zebrafish brain, the ligands used here displace more
than 100%. f, MEGY; Œ, (D-Ala2)-MEGY; , (D-Ala2, Val5)-MEGY; F,
Met-enkephalin; , morphine. Brains were extracted as previously de-
scribed, and either 30 (zebrafish) or 100 g (rat) of protein was incubated
with [3H]MEGY and increasing concentrations of the unlabeled ligands
ranging from 0.3 nM to 10 M for 1.5 h at 25°C in a final volume of 500
l. Nonspecific binding was determined with 10 M naloxone.
TABLE 1
Ki values of MEGY and its two analogs in zebrafish and rat brain membranes obtained from competition binding assays using 
3Hdiprenorphine
Percentage of displacement of 3Hdiprenorphine is shown at a concentration of 10 M of the unlabeled ligand.
Ligand Ki, Zebrafish Brain
Hill
Coefficient
Displacement in
Zebrafish Brain Ki, Rat Brain
Hill
Coefficient
Displacement in
Rat Brain
nM % nM %
MEGY Ki1  1.17  0.27 0.31 74.28  4.20 Ki  22.10  1.57 0.90 89.09  0.80
Ki2  673  136
(D-Ala2)-MEGY Ki  12.40  2.67 0.65 63.89  2.69 Ki  29.90  7.97 0.62 85.45  2.23
(D-Ala2, Val5)-MEGY Ki  137  26.45 0.85 54.64  2.36 Ki  72.20  7.15 0.81 79.39  3.30
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MEGY and its two analogs to bind to the opioid sites and to
compete for the opioid binding sites with other conventional
ligands. These assays have established that the peptidic
agents tested here can effectively displace the opioid binding
shown by diprenorphine, not only in zebrafish brain homog-
enates but also in membrane preparations from rat brain, a
mammalian model. MEGY shows a two-site displacement in
zebrafish brain, with one high-affinity site and one site with
lower affinity, which suggests that this peptide may act on
two or more different receptors with different affinities. Pre-
liminary work from our laboratory suggests that MEGY
binds to the  receptors from zebrafish (V. Gonza´lez-Nun˜ez,
R. E. Rodriguez, A. Barrallo, and J. Traynor, unpublished
results). The fact that a ligand shows a biphasic curve in
competition binding assays has been previously reported for
other ligands, such as morphiceptin (Chang et al., 1981). In
the rat, the analog (D-Ala2)-MEGY shows a similar Ki and
percentage of displacement at 10 M than MEGY, thus in-
dicating that the change of Gly by a D-Ala does not affect the
ability of the ligand to bind to opioid sites. However, the
(D-Ala2, Val5)-MEGY analog displays a higher Ki, revealing
that the change of Met by Val entails a loss in binding
affinity. These results can be taken into consideration for
future opioid ligand design because an effective peptidic li-
gand should have the methionine in the fifth position,
whereas the Gly can be replaced by another small residue
that might confer resistance against protease degradation.
As seen in Fig. 2, the peptides analyzed here can displace
almost all the diprenorphine binding in rat brain, whereas in
zebrafish brain, the native peptide displaces only up to 74%.
This difference can be explained if we postulate that di-
prenorphine may bind to the opioid sites present in zebrafish
brain in a different manner than to those present in mam-
malian brain. These results are interesting because it may be
inferred that diprenorphine can be considered as a good and
selective ligand to label opioid sites in mammalian brain,
whereas in zebrafish diprenorphine does not seem to show
such selectivity and thus, other opioid ligands are not able to
displace up to 100% of its binding.
In competition binding assays with [3H]MEGY, we have
used this same peptide as an internal control and then the
two MEGY analogs to establish the change in affinity
triggered by the change in structure. In addition, we have
also used Met-enkephalin since this peptide is present as
an endogenous opioid ligand in both species and morphine
because of its great medicinal importance. Besides, the use
of morphine led us to examine the ability of a nonpeptidic
opiate to compete for peptidic-labeled opioid sites. As seen
in Fig. 3 and Table 2, the changes in the peptide structure
comprise losses in binding affinity in zebrafish brain, the
MEGY-Val analog being the one with the highest Ki. How-
ever, in rat brain, the substitution of Gly by a D-Ala does
not entail a change in the inhibition constant Ki, probably
because this modification does not cause a change in size or
in charge of the ligand. Met-enkephalin shows a similar
pattern to the one observed for MEGY in zebrafish brain,
whereas in rat brain it displays a lower Ki value, possibly
because it is an endogenous ligand for mammalian opioid
receptors, although to our knowledge the MEGY peptide is
not naturally present in tetrapods. The alkaloid opiate
morphine can displace [3H]MEGY binding in a very similar
manner in both brain membranes tested in this work, thus
confirming our previous results in which we have shown
that morphine also acts on zebrafish opioid receptors (Rod-
riguez et al., 2000). Finally, as seen in Fig. 3 and Table 2,
all the ligands studied are able to present a higher dis-
placement than naloxone, especially when acting on ze-
brafish brain. This observation can be explained if we
consider that the [3H]MEGY peptide, apart from binding to
naloxone-sensitive opioid sites, also binds to some sites
that are not recognized by naloxone. Hence, the sites rec-
ognized by naloxone should be considered as classical opi-
oid sites, and the naloxone-insensitive sites should be
named as nonclassical opioid sites. Therefore, the expres-
sion “nonopioid” could be used accurately when an opioid
ligand acts on a different receptor than the opioid recep-
tors (e.g., the Met-enkephalin and its derivatives on the
cytosolic opioid growth factor receptor) (Zagon et al., 2002).
Under this consideration, the endogenous peptides, as well
as the peptidic opioid analogs and morphine, bind to the
putative nonclassical opioid sites; hence, we believe that
they are acting on the opioid receptors present in zebrafish
brain. This can be explained if we consider that some parts
of the opioid binding pocket may allow distinct agents,
such as peptidic ligands and synthetic agonists and antag-
onists, to recognize different motifs when they bind to the
opioid receptors; thus, not all sites are recognized by some
ligands. This hypothesis has previously been raised by
other authors (Befort et al., 1996). Our data point to the
possibility that the antagonist naloxone does not bind to
some sites that are recognized by the agonists; hence, the
MEGY peptide presents a higher selectivity for recognizing
the opioid binding sites in zebrafish.
In conclusion, our results prove that the MEGY peptide
acts as a highly specific endogenous ligand for the zebrafish
opioid receptors and also binds with high affinity to their
mammalian counterparts. Our work reveals that the ze-
brafish opioid peptide MEGY presents a different binding
profile than other opioid agonists; therefore, this ligand can
be used as a new tool to investigate the ligand-receptor in-
TABLE 2
Ki values of several ligands in zebrafish and rat brain membranes obtained from competition binding assays using 
3HMEGY
Percentage of displacement of 3HMEGY is shown at a concentration of 10 M of the unlabeled ligand.
Ligand Ki, Zebrafish Brain
Hill
Coefficient
Displacement in
Zebrafish Brain Ki, Rat Brain
Hill
Coefficient
Displacement in
Rat Brain
nM % nM %
MEGY Ki  2.89  0.85 0.9598 106.85  1.40 Ki  4.21  1.41 1.063 109.51  1.19
(D-Ala2)-MEGY Ki  7.65  1.99 1.616 112.72  4.90 Ki  4.45  1.21 0.9634 100.16  1.48
(D-Ala2, Val5)-MEGY Ki  25.93  3.47 0.8978 110.25  2.46 Ki  21.06  2.71 0.9655 100.15  0.92
Met-enkephalin Ki  2.01  0.59 0.8618 108.43  1.65 Ki  2.40  0.29 0.8680 102.55  1.06
Morphine Ki  14.15  2.61 0.9744 114.12  2.69 Ki  7.23  1.57 0.4062 97.44  3.78
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teractions in relation to the modulation of pain and drug
addiction.
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